Slovak scientists join forces with private investors to bring personalized treatment to breast cancer patients

Slovak biotech company MultiplexDX, a leader in biotechnology, has renewed its partnership with investment platform Crowdberry, and together they have launched a new investment campaign with a record target of €7.5 million. The campaign aims to raise private capital to support breakthrough diagnostics enabling personalized breast cancer treatment.

The unique Multiplex8+ diagnostic test enables accurate and rapid diagnosis of breast cancer by identifying genetic and molecular changes in the cell, thus increasing treatment success and improving patient prognosis. Investor money will enable the diagnostic test to be provided directly to practices as well as providing frequent reimbursement for innovative treatments.

The test not only refines the diagnosis itself towards determining the specific subtype of cancer, but more importantly, it provides information that allows oncologists to prioritise and tailor treatment to the patient. As a result, this increases the success rate of treatment and, most crucially, reduces the chance of recurrence.

"Inaccurate diagnosis and the resulting inadequate treatment of breast cancer patients results in only a 50% treatment success rate and a higher chance of cancer recurrence. The MultiplexDX team of experts is using its discoveries in diagnostics to help doctors set up personalised cancer treatments and consequently save patients’ lives. With the help of private capital from investors on the Crowdberry platform, we will be able to accelerate our development and bring a breakthrough diagnostic test to the market," revealed Pavol Čekan, CEO and founder of MultiplexDX.

First successes are already a reality

The first successes with detailed diagnostics are now behind MultiplexDX. Approximately one month – that is the period from the initial diagnosis with MultiplexDX to the successful results with clear efficacy in the first patient.